疏水性药物的配送平台:前药物方法与自组装的多层药物相结合
Benjamin Thierry1, Piotr Kujawa, Cathy Tkaczyk
1Department of Biomedical Engineering, McGill University, H3A 2B Montreal, Canada.
Journal of the American Chemical Society
|February 11, 2005
概括
这项研究引入了一种新的药物递送平台,使用宏分子前药物和对像帕克利塔塞尔这样的疏水药物进行层次组装. 这种方法有效释放药物,导致显著的癌细胞死亡.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 疏水性药物,如帕克利塔塞尔,由于溶解性差,在有效的输送方面面临挑战.
- 大分子前药物和层层组装 (LbL) 为控制药物释放提供了潜在的解决方案.
研究的目的:
- 设计和描述一种用于疏水性药物的新型药物输送平台.
- 为了利用帕克利塔塞尔的氨酸 Ester 前药物与LbL组装的多层聚电解质.
主要方法:
- 合成了帕克利塔塞尔的氨酸 Ester 前药物.
- 聚电解质多层的层层组装,其中包含药物.
- 使用石英晶体微平衡,原子力显微镜和紫外线光谱学进行了表征.
主要成果:
- 帕克利塔克塞尔与氨酸的结合并没有影响其活性.
- 疏水性药物组没有妨碍LbL多层结构.
- 链的水解触发了药物释放,导致显著的癌细胞死亡.
结论:
- 开发的平台有效地提供疏水性药物,证明了癌症治疗的潜力.
- 这种方法可以应用于各种基质,包括合物,植入物和组织,用于新的治疗策略.
相关概念视频
Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


